| Daniel R Whiting, MD | |
|
2740 South Ave W Ste 101, Missoula, MT 59804-5137 | |
| (406) 728-6101 | |
| (406) 721-3278 |
| Full Name | Daniel R Whiting |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 17 Years |
| Location | 2740 South Ave W Ste 101, Missoula, Montana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356637995 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | 57896 (Montana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Community Medical Center | Missoula, MT | Hospital |
| St. Patrick Hospital | Missoula, MT | Hospital |
| Marcus Daly Memorial Hospital - Cah | Hamilton, MT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Northern Rockies Orthopaedics, Pllp | 6507766227 | 24 |
News Archive
ImmunoCellular Therapeutics, a biotechnology company focused on the development of novel immune-based cancer therapies, today announced long-term data from a Phase I clinical trial of ICT-107, the Company's lead cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.
Stress affects most Americans at one point or another. Although some people are genetically more susceptible to the stressors of daily life than others, most could benefit from learning how to lower that stress before it negatively affects their physical and mental health.
The Cleveland Plain Dealer "Ohioans who haven't been able to find affordable health insurance because of pre-existing conditions can get high-risk coverage as soon as Sept. 1. The state will receive $152 million in federal money to pay for the new program a product of the health-care reform bill President Barack Obama signed into law in March. That's enough to cover about 5,000 people, said Carly Glick, spokeswoman for the Ohio Department of Insurance."
Physicians are anticipating the arrival of new oral therapies for multiple sclerosis patients, with initial research showing very high awareness of oral candidates, particularly Novartis' Gilenya, which received FDA approval for relapsing forms of the disease in late September. The majority of neurologists expect Gilenya to be very useful as a therapy and trial of the drug is predicted to be strong, according to new research by GfK HealthCare.
Researchers report that a digital 3D foot scanner can detect foot deformities in patients with rheumatoid arthritis, even before clinical signs are present.
› Verified 4 days ago
| Entity Name | Northern Rockies Orthopaedics, Pllp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922008077 PECOS PAC ID: 6507766227 Enrollment ID: O20040109000894 |
News Archive
ImmunoCellular Therapeutics, a biotechnology company focused on the development of novel immune-based cancer therapies, today announced long-term data from a Phase I clinical trial of ICT-107, the Company's lead cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.
Stress affects most Americans at one point or another. Although some people are genetically more susceptible to the stressors of daily life than others, most could benefit from learning how to lower that stress before it negatively affects their physical and mental health.
The Cleveland Plain Dealer "Ohioans who haven't been able to find affordable health insurance because of pre-existing conditions can get high-risk coverage as soon as Sept. 1. The state will receive $152 million in federal money to pay for the new program a product of the health-care reform bill President Barack Obama signed into law in March. That's enough to cover about 5,000 people, said Carly Glick, spokeswoman for the Ohio Department of Insurance."
Physicians are anticipating the arrival of new oral therapies for multiple sclerosis patients, with initial research showing very high awareness of oral candidates, particularly Novartis' Gilenya, which received FDA approval for relapsing forms of the disease in late September. The majority of neurologists expect Gilenya to be very useful as a therapy and trial of the drug is predicted to be strong, according to new research by GfK HealthCare.
Researchers report that a digital 3D foot scanner can detect foot deformities in patients with rheumatoid arthritis, even before clinical signs are present.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Daniel R Whiting, MD 2740 South Ave W Ste 101, Missoula, MT 59804-5137 Ph: (406) 728-6101 | Daniel R Whiting, MD 2740 South Ave W Ste 101, Missoula, MT 59804-5137 Ph: (406) 728-6101 |
News Archive
ImmunoCellular Therapeutics, a biotechnology company focused on the development of novel immune-based cancer therapies, today announced long-term data from a Phase I clinical trial of ICT-107, the Company's lead cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.
Stress affects most Americans at one point or another. Although some people are genetically more susceptible to the stressors of daily life than others, most could benefit from learning how to lower that stress before it negatively affects their physical and mental health.
The Cleveland Plain Dealer "Ohioans who haven't been able to find affordable health insurance because of pre-existing conditions can get high-risk coverage as soon as Sept. 1. The state will receive $152 million in federal money to pay for the new program a product of the health-care reform bill President Barack Obama signed into law in March. That's enough to cover about 5,000 people, said Carly Glick, spokeswoman for the Ohio Department of Insurance."
Physicians are anticipating the arrival of new oral therapies for multiple sclerosis patients, with initial research showing very high awareness of oral candidates, particularly Novartis' Gilenya, which received FDA approval for relapsing forms of the disease in late September. The majority of neurologists expect Gilenya to be very useful as a therapy and trial of the drug is predicted to be strong, according to new research by GfK HealthCare.
Researchers report that a digital 3D foot scanner can detect foot deformities in patients with rheumatoid arthritis, even before clinical signs are present.
› Verified 4 days ago
Taylor Buckley, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2740 South Ave W Ste 101, Missoula, MT 59804 Phone: 406-728-6101 Fax: 406-721-3278 | |
Dr. Stephen George Powell, M.D. Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 2831 Fort Missoula Rd, Suite 232, Missoula, MT 59804 Phone: 406-728-6101 Fax: 406-721-3278 | |
Dr. James Joseph Gholson, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2360 Mullan Rd Ste C, Missoula, MT 59808 Phone: 406-721-4436 Fax: 406-721-6053 | |
Joseph Fox, M.D. Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 2835 Fort Missoula Rd Ste 201, Missoula, MT 59804 Phone: 406-327-4730 | |
Paul Andrew Puckett, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2360 Mullan Rd, Suite C, Missoula, MT 59808 Phone: 406-721-4436 Fax: 406-721-6053 | |
Dr. Larry R. Stayner, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2740 South Ave W Ste 101, Missoula, MT 59804 Phone: 406-728-6101 Fax: 406-721-3278 | |
Dr. Zackery W Witte, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2360 Mullan Rd Ste C, Missoula, MT 59808 Phone: 406-721-4436 Fax: 406-721-6053 |